Tsumura (TSE:4540) Current Accrued Expense : 円0 Mil (As of Mar. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Tsumura Current Accrued Expense?

Tsumura's Current Accrued Expense for the quarter that ended in Mar. 2024 was 円0 Mil.

Tsumura Current Accrued Expense Historical Data

The historical data trend for Tsumura's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tsumura Current Accrued Expense Chart

Tsumura Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Current Accrued Expense

Get a 7-Day Free Trial

Tsumura Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Tsumura Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Tsumura Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Tsumura's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Tsumura (TSE:4540) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tsumura & Co (TSE:4540) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

TSMRF:USA

Address

2-17-11, Akasaka, Minato-ku, Tokyo, JPN, 107-8521

Website

http://www.tsumura.co.jp

Tsumura & Co is a specialty and generic drug manufacturing company. The company generates most of its revenue through prescription Kampo products, followed by over-the-counter medicines. Tsumura promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company considers strategic collaboration agreements to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Tsumura (TSE:4540) Headlines

No Headlines